

## **NephroGenex Inc**

### **COMPANY AND PIPELINE OVERVIEW REPORT**

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 08-Feb-2015

#### **THOMSON REUTERS**

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 7

Product Portfolio Summary..... 11

Product Portfolio Drugs..... 14

[Return to Table of Contents](#)

# NephroGenex Inc

## COMPANY OVERVIEW

Company Name	NephroGenex Inc
Parent Company Name	NephroGenex Inc
Website	<a href="http://www.nephrogenex.com/">http://www.nephrogenex.com/</a>
Country	US
Number of Drugs in Active Development	2
Number of Inactive Drugs	2
Number of Patents as Owner	3
Number of Patents as Third Party	0
Number of Deals	7
Key Indications	Diabetic nephropathy, Renal injury, Renal failure
Key Target-based Actions	
Key Technologies	Intravenous formulation, Small molecule therapeutic, Synthetic method

## COMPANY PROFILE

### SUMMARY

NephroGenex is a biotechnology company based in Cary, NC. The company is applying the latest advances in molecular profiling technologies with regard to developing drugs for the potential treatment of kidney disease, and is acquiring commercial rights to clinical-stage candidates that exhibit activity toward established renal pathology, as well as identifying renal molecular profiles and biomarkers that identify patients that are more likely to respond to therapy.

### LICENSING AGREEMENTS

In May 2005, NephroGenex acquired exclusive commercial rights to glomerular transcriptome profiling technology developed by Drs. Karl Tryggvason and Christer Betsholtz of the Department of Medical Biochemistry and Biophysics at the Karolinska Institute. The technology utilizes GlomChip, a DNA chip developed to measure expressed genes in the glomerulus.

### FINANCIAL

In November 2014, NephroGenex closed a \$12 million term loan facility with East West Bank, which includes an immediate \$7 million draw, with the additional \$5 million available upon the achievement of certain milestones before the end of May 2015. The bank facility was to mature in 2018.

In February 2014, the company expected to raise gross proceeds of \$37,200,000 from an IPO of 3,100,000 shares of its common stock, priced at \$12.00 per share. The underwriters were granted a 45-day option to buy up to an additional 465,000 shares of common stock to cover any over-allotments. At that time, the offering was expected to close on February 14, 2014. Also at that time, the company's common stock was approved for listing on the NASDAQ Capital Market and trading was expected to begin under the ticker symbol "NRX" on February 11, 2014. Later that month, trading of shares began; and the IPO was closed and the company raised net proceeds of \$33.4 million.

## COMPANY FINANCIALS

### SHARE INFORMATION

Close Price (USD)	6.86
Change (USD)	0.01 (0.15%)

[Return to Table of Contents](#)



<b>Previous Close Price (USD)</b>	6.85
<b>Volume</b>	30,452
<b>52-Week High (USD)</b>	17.98
<b>52-Week Low (USD)</b>	3.96
<b>Date</b>	06-Feb-2015
<b>Exchange</b>	NASDAQ(COMPOSITE)
<b>Current Number of Shares Outstanding</b>	8,861,614
<b>Current Market Capitalization</b>	60,790,672
<b>EPS (Date Reported)</b>	-0.71106

### STOCK PERFORMANCE




### MAJOR SHAREHOLDERS

Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
Rho Capital Partners, Inc.	Private Equity	United States	1,052,966	11.88	-273,860	-0.21	06-Jan-2015

[Return to Table of Contents](#)

FINANCIAL PERFORMANCE



	2011	2013	2012		
Sales (USD M)	0	0	0		
Operating Income (USD M)	-2.624709	-2.505711	-2.701867		
Net Income (USD M)	-1.851797	-6.304663	-2.904164		

[Return to Table of Contents](#)



## Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2014 Q3	0	-4.427	-4.415
2014 Q2	0	-5.435	-5.423
2014 Q1	0	-1.491801	-1.700316
2013 Q4	0	-1.048476	-4.153833
2013 Q3	0	-0.679	-0.874
2013 Q2	0	-0.375	-0.803
2013 Q1	0	-0.402697	-0.473824
2012 Q4	0	-0.737765	-0.803809

## BALANCE SHEET

### Assets (USD M)

	2011	2012	2013		
Cash & Short Term Investments	1.239557	0.323678	2.13199		
Inventories - Total	0	0	0		
Current Assets - Total	1.27835	0.3477	2.143701		
Property, Plant And Equipment - Net	0.023946	0.003143	0.010826		
Other Assets - Total	0.004098	0.013586	0.465176		
Total Assets	1.306394	0.364429	2.619703		

### Liabilities (USD M)

	2011	2012	2013		
Accounts Payable	0.040313	0.07792	0.047865		
Short Term Debt & Current Portion Of Long Term Debt	2.1	3.354822	7.91687		
Current Liabilities - Total	6.496823	8.333516	16.805436		
Long Term Debt	0	0	0		
Deferred Taxes	0	0			
Other Liabilities	0	0	0		
Total Liabilities	6.496823	8.333516	16.805436		

[Return to Table of Contents](#)

## Stockholders Equity (USD M)

	2011	2012	2013		
Minority Interest	0	0	0		
Preferred Stock	62.9	62.9	65		
Common Stock	0.00032	0.00032	0.00032		
Total Liabilities & Shareholders' Equity	1.306394	0.364429	2.619703		

## FORECASTS

### EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	-2.45	-1.73	-2.45

### Other Forecasts

Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015			-22.32	0

[Return to Table of Contents](#)




## PRODUCT PORTFOLIO SUMMARY

### DRUGS

#### Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Genitourinary disease	2	1	3
Gastrointestinal disease	0	1	1
Injury	1	0	1
Metabolic disorder	0	1	1
Endocrine disease	0	1	1

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Discovery	1
No Development Reported	2

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	0	0	1	0	1
Drug - Development/Commercialization License	0	0	2	0	2
Drug - Commercialization License	0	0	1	0	1
Drug - Manufacturing/Supply	0	0	1	0	1
Drug - Development Services	0	0	2	0	2

## CLINICAL TRIALS

[Return to Table of Contents](#)

## Trials by Condition Studied

Condition Studied	Ongoing	All
Genitourinary disease	1	4

## Trials by Phase

Phase	Ongoing	All
Phase 3	1	1
Phase 2	0	2
Phase 1	0	1

## Phase Definitions

### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	1	0	1
Endocrine disease	2	0	2
Gastrointestinal disease	2	0	2
Genitourinary disease	4	0	4
Musculoskeletal disease	1	0	1
Ocular disease	1	0	1
Metabolic disorder	3	0	3
Neurological disease	1	0	1
Inflammatory disease	1	0	1

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### pyridoxamine dihydrochloride

<b>Drug Name</b>	pyridoxamine dihydrochloride
<b>Key Synonyms</b>	Pyridorin
<b>Originator Company</b>	BioStratum Inc
<b>Active Companies</b>	NephroGenex Inc, Kowa Co Ltd
<b>Inactive Companies</b>	BioStratum Inc
<b>Highest Status</b>	Phase 3 Clinical
<b>Active Indications</b>	Psychiatric disorder, Diabetic nephropathy
<b>Target-based Actions</b>	
<b>Other Actions</b>	Glycosylation inhibitor, Protectant, Antioxidant agent
<b>Technologies</b>	Oral formulation, Small molecule therapeutic
<b>Last Change Date</b>	08-Jan-2015

### pyridoxamine dihydrochloride (intravenous, acute kidney injury), NephroGenex

<b>Drug Name</b>	pyridoxamine dihydrochloride (intravenous, acute kidney injury), NephroGenex
<b>Key Synonyms</b>	Pyridorin
<b>Originator Company</b>	NephroGenex Inc
<b>Active Companies</b>	NephroGenex Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Renal injury
<b>Target-based Actions</b>	
<b>Other Actions</b>	Glycosylation inhibitor, Protectant, Antioxidant agent
<b>Technologies</b>	Intravenous formulation, Small molecule therapeutic
<b>Last Change Date</b>	13-Nov-2014

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

